OGN · Organon & Co.
$13.72
+0.00 (+0.00%)
At close · Aug 14
Going-concern doubt
— cleared Jul 31, 2026
The latest filing no longer states the doubt (first flagged May 4, 2026).
View the 10-Q filed Jul 31, 2026Market Cap
$3.60B
Shares
262.61M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Kevin Ali | — | $15,813,296 |
| Joseph Morrissey | — | $5,772,848 |
| Matthew Walsh | EVP and Chief Financial Officer | $5,686,204 |
| Juan Camilo Arjona Ferreira | EVP and Head of R&D and Chief Medical Officer | $3,822,487 |
| Rachel Stahler | EVP and Chief Digital & Growth Officer | $3,551,619 |
| Kirke Weaver | EVP, General Counsel and Corporate Secretary | $3,542,975 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kevin Ali | Chief Executive Officer | $17,117,424 |
| Former Chief | Executive Officer | $17,117,424 |
| Matthew Walsh | EVP and Chief Financial Officer | $5,746,922 |
| Susanne Fiedler | Former EVP and Chief Commercial Officer | $4,197,282 |
| Joseph Morrissey | EVP and Head of Manufacturing and Supply | $4,129,939 |
| Interim Chief | Executive Officer | $4,129,939 |
| Juan Camilo Arjona Ferreira | EVP and Head of R&D and Chief Medical Officer | $3,599,751 |
| Kirke Weaver | EVP, General Counsel and Corporate Secretary | $3,524,103 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kevin Ali | Chief Executive Officer | $14,832,272 |
| Former Chief | Executive Officer | $14,832,272 |
| Matthew Walsh | EVP and Chief Financial Officer | $5,212,866 |
| Sandra Milligan | Former EVP and Head of Research and Development | $4,356,713 |
| Susanne Fiedler | Former EVP and Chief Commercial Officer | $3,836,401 |
| Joseph Morrissey | EVP and Head of Manufacturing and Supply | $3,737,009 |
| Interim Chief | Executive Officer | $3,737,009 |
| Kirke Weaver | EVP, General Counsel and Corporate Secretary | $3,192,693 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin Ali | Chief Executive Officer | $13,532,980 |
| Matthew Walsh | EVP and Chief Financial Officer | $5,306,585 |
| Sandra Milligan | Former EVP and Head of Research and Development | $4,269,640 |
| Susanne Fiedler | Former EVP and Chief Commercial Officer | $3,656,038 |
| Joseph Morrissey | EVP and Head of Manufacturing and Supply | $3,295,199 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin Ali | Chief Executive Officer | $18,550,737 |
| Matthew Walsh | EVP and Chief Financial Officer | $6,757,065 |
| Susanne Fiedler | EVP and Chief Commercial Officer | $5,316,274 |
| Sandra Milligan | Former EVP and Head of Research and Development | $4,932,735 |
| Deborah H. Telman | EVP and General Counsel and Corporate Secretary | $4,112,953 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robert Essner | Lead Independent Director | Appointed | 2025-10-27 |
| Joseph Morrissey | Interim Chief Executive Officer (and principal executive officer) | Appointed | 2025-10-27 |
| Carrie S. Cox | Executive Chair for an interim period | Appointed | 2025-10-27 |
| Kevin Ali | member of the Company's Board of Directors | Resigned | 2025-10-27 |
| Kevin Ali | Chief Executive Officer | Resigned | 2025-10-27 |
| Ramona A. Sequeira | Board of Directors | Appointed | 2025-04-15 |
| Martha E. McGarry | member of the Board and as a member of the Talent Committee of the Board | Resigned | 2024-12-06 |
| Deborah H. Telman | Executive Vice President, General Counsel and Corporate Secretary | Resigned | 2022-07-12 |
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
582 filings
558 filers
Visit website
Investor relations